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Abstract
Background: Tumor patients exhibit an increased peripheral demand of fatty acids and protein. Contrarily, tumors
utilize glucose as their main source of energy supply. Thus, a diet supplying the cancer patient with sufficient fat
and protein for his demands while restricting the carbohydrates (CHO) tumors thrive on, could be a helpful
strategy in improving the patients’ situation. A ketogenic diet (KD) fulfills these requirements. Therefore, we
performed a pilot study to investigate the feasibility of a KD and its influence on the quality of life of patients with
advanced metastatic tumors.
Methods: Sixteen patients with advanced metastatic tumors and no conventional therapeutic options participated
in the study. The patients were instructed to follow a KD (less than 70 g CHO per day) with normal groceries and
were provided with a supply of food additives to mix a protein/fat shake to simplify the 3-month intervention
period. Quality of life [assessed by EORTC QLQ-C30 (version 2)], serum and general health parameters were
determined at baseline, after every two weeks of follow-up, or after drop out. The effect of dietary change on
metabolism was monitored daily by measuring urinary ketone bodies.
Results: One patient did not tolerate the diet and dropped out within 3 days. Among those who tolerated the
diet, two patients died early, one stopped after 2 weeks due to personal reasons, one felt unable to stick to the
diet after 4 weeks, one stopped after 6 and two stopped after 7 and 8 weeks due to progress of the disease, one
had to discontinue after 6 weeks to resume chemotherapy and five completed the 3 month intervention period.
These five and the one who resumed chemotherapy after 6 weeks report an improved emotional functioning and
less insomnia, while several other parameters of quality of life remained stable or worsened, reflecting their very
advanced disease. Except for temporary constipation and fatigue, we found no severe adverse side effects,
especially no changes in cholesterol or blood lipids.
Conclusions: These pilot data suggest that a KD is suitable for even advanced cancer patients. It has no severe
side effects and might improve aspects of quality of life and blood parameters in some patients with advanced
metastatic tumors.
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Introduction
In the recent past, a remarkable growing interest could
be observed in scientific literature concerning the striking
carbohydrate metabolism of tumor tissue. In contrast to
normal tissues, which can metabolize glucose, fatty acids
and ketone bodies, according to Warburg’s observations,
many tumors depend heavily on glucose for their meta-
bolic demands and ferment it to lactate - even under
sufficient oxygen supply [1,2]. For this purpose, tumor
cells have a remarkable up regulation of glucose trans-
porter molecules on their surface. In addition, there is a
frequent over expression of several key enzymes of glyco-
lysis and attached pathways [3,4]. This prominent change
in metabolism and associated enzymes/receptors could
provide attractive targets fort u m o r - s p e c i f i ct h e r a p i e s .
Several substances such as specific drugs interfering with
the Warburg effect are under investigation [5-7]. How-
ever, to date, no safe and established therapy is available
that targets tumor metabolism to fight cancer.
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able. Since 1885, when E. Freund observed that patients
with malignant disease can develop spontaneous hyper-
glycaemia [8], there has been episodic interest in the
association of the altered glucose metabolism with the
path of nutrition and neoplasia in man. As early as
1924, Händel and Tadeuma summarized the findings in
those days as: “a diet rich in carbohydrates has a pro-
nounced stimulating impact on tumor growth” [9].
Reckoning the metabolic situation in the tumor patient’s
body, it could not be overseen, that increasing insulin
resistance [10] and fatty acid oxidation [11] is character-
istic for healthy tissue. In contrast, tumor cells often
lack the ability to use fatty acids or ketone bodies (acet-
oacetate, beta-hydroxybutyrate) as an energy source and
could even be harmed by them [12-15]. In an elegant in
vivo setting, Holm et al have proven the different sub-
strate utilization rates of tumor tissue and peripheral tis-
sue in colon cancer patients. They clearly demonstrated
that the peripheral tissue of the patients preferably uti-
lized fatty acids and ketone bodies for energy demands,
while the tumour showed the Warburg effect [16].
Thus, supporting fatty acid metabolism and inhibiting
glucose metabolism should “feed” the body while neither
supporting nor harming the tumor. LowCarb/HighFat
(LCHF) diets and the strictly carbohydrate restricted
ketogenic diet (KD) fulfill this purpose. Here, ketone
bodies are produced as intermediate catabolic products
of fatty acid breakdown by the liver.These ketone bodies
can substitute glucose as an energy source in nearly
every healthy tissue including the brain, even in a nutri-
tional situation completely devoid of carbohydrates
(CHO). This was impressively shown nearly one hun-
dred years ago by the arctic explorer Vilhjalmur Stefans-
son, whose clinically controlled one year meat only diet
impaired neither his nor his partner’s physical and men-
tal fitness [17].
Ketogenic diets have been used for the treatment of
epilepsy in children since the 1920s [18]. Currently, the
number of centers applying a KD to treat children with
drug resistant epilepsy and the number of clinical studies
have dramatically increased [19-21]. Other than classical
KDs for the treatment of epilepsy which are in general
80% fat, 15% protein and 5% CHO, a KD with 60% fat,
30% protein and 10% carbohydrate was introduced by
Atkins in the 1970s to combat obesity [22]. Nowadays,
the Atkins diet is very popular and although it’sl o n g -
term effect on weight loss is discussed controversially
[23] undoubtedly it has a positive effect on the triglycer-
ide and insulin levels [24,25] and no adverse side effects.
In 1995, two female pediatric patients with advanced
stage astrocytoma tumors were treated at the Case Wes-
tern Reserve University, Cleveland, Ohio with a KD
based on medium chain triglycerides (MCT) as fat
source [26]. The glucose uptake of the tumor decreased
remarkably in both children and one of the patients was
free of disease progression for 12 months of follow up
and was still alive 10 years later (Nebeling L, personal
communication). Several groups in the first decades of
the last century reported that a diet low in carbohy-
drates and rich in fat and protein was an effective treat-
ment in animal settings [9,27,28]. Although different in
experimental details, all three groups agreed that with-
drawal of carbohydrates and enrichment of fat in the
chow fed ad libitum to tumor bearing animals led to a
strong reduction in tumor growth. In this respect, data
from the Seyfried lab demonstrated, that a calorie
reduced KD was able to considerably reduce the intra-
cerebral growth of malignant brain cancer cells in mice
[13] and a tumor in a female glioblastoma patient [29],
however, at the expense of a dramatic weight loss. Ear-
lier, it was shown, that the ketone body beta-hydroxybu-
tyrate not only inhibited the growth of several tumor
cells in vitro, but also reduced the number of B16 mela-
noma deposits in the lungs of C57BL/6 mice by two
thirds [30]. This inhibitory effect of beta-hydroxybuty-
rate and acetoacetate on tumor cell growth was con-
firmed in colon and breast cancer cell lines [14], as well
as in neuroblastoma cells [15].
It has been shown recently, that a KD significantly
decreased tumor volume and increased survival time in
a mouse model for prostate cancer, compared to ani-
mals fed the standard “Western diet” [31]. Of impor-
tance, this effect was observed without restricting total
calories and the mice did not lose body weight, a situa-
tion desirable in humans, especially in advanced cancer
patients. In addition, a chow enriched in Omega-3 fatty
acids, even if it was non-ketogenic, has been shown to
reduce tumor growth rate and tumor cell proliferation
significantly in animal models [32]. Our own preliminary
experiments have shown that the application of an
unrestricted ketogenic diet enriched with Omega-3 fatty
acids and MCT delayed tumor growth in a mouse xeno-
graft model [33].
Based on data from literature and our own observa-
tions, an LCHF diet was established to treat advanced
cancer patients that restricted CHO to a maximum of
70 g/day, was enriched in fat - with emphasis on
Omega-3 fatty acids - and nonrestricted in overall cal-
ories. The aims of the pilot study presented here were
a) to prove the tolerability of such a diet in advanced
tumor patients with no further established (classical)
therapeutic options b) to see which effect it has on the
quality of life, as determined by EORTC QLQ-C30 (ver-
sion 2) [34] and c) to analyze the effects of such a diet
on classical blood parameters and the course of disease.
No specific tumor entity was chosen, the diet was
offered to all patients who fulfilled the inclusion criteria.
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Patients
The study was approved by the ethics committee of the
Medical Faculty of the University of Wuerzburg, Ger-
many. All participants signed an informed consent and
obtained the approval of their home-oncologist.
Inclusion criteria for the study were:
1) advanced/metastatic tumor stage of solid malignant
tumors of different origins,
2) no actual established therapeutic option available
(no chemo- or radiotherapy),
3) measurable parameter for follow up (tumor-marker
in serum or tumor visible in CT/PET/MRI),
4) acceptable general condition (as determined by the
Karnofsky performance status (KPS) scale; [35])
5) laboratory values had to be within nearly normal
range: red and white blood cell count, hemoglobin, pla-
telet count, sodium, potassium, calcium, glycohemoglo-
bin, AST (serum glutamic-oxaloacetic transaminase),
ALT (serum glutamic-pyruvic transaminase), bilirubin,
blood urea nitrogen, creatinine, uric acid, cholesterol,
high and low density lipoproteins, triglycerides, lipase,
total protein, albumin, prothrombin time, thyroid stimu-
lating hormone. No signs of systemic inflammation
(very high CRP and leukocyte counts) should be
present.
Patients with mildly elevated (less than 20%) levels of
liver enzymes, bilirubin, creatinine (up to 1.6 mg/dl),
uric acid, blood urea nitrogen (up to 68 mg/dl), trigly-
cerides, cholesterol or lipase were allowed in the study.
Patients with slightly lowered (less than 20%) white
blood cell count, hemoglobin, cholesterol or triglycerides
were also allowed to participate. Low-dose thyroid sti-
mulating hormone was allowed for patients with thyroid
carcinoma.
6) Patients had to feel capable of following the dietary
guidelines and shopping and cooking, perhaps with sup-
port from a family member.
The patients included in the study and their character-
istics are listed in Table 1.
Study design
Type of study: Prospective observational pilot study to
investigate if a diet very low in CHO and rich in fatty
acids is safe and feasible for advanced cancer patients;
without adverse side effects and with improvement of
their quality of life. The course of the study is shown in
Figure 1.
Nutrition
The patients started the diet after having been thor-
oughly instructed in the principles and practical
Table 1 Data of patients enrolled in the study
No Age Sex Primary tumor Measurement of
disease
Metastases Therapy between primary surgery and start of diet
1 47 f Ovarian cancer CT, CA 125 LI, LN, PC 10 × Taxol/Carboplatin; 10 × Hycamptin
2 46 f Breast Cancer PET MPE, AS Radiatio, 6 × [CMF]; 12 × [Epirubicin/Cyclophosphamid[, 14 × [Taxotere
[, 2 × [Gemcetabine]
3 48 f Granulosa cell
tumor
CT, PET, Inhibin LI, MI 6 × [Carboplatin/Epirubicin/Cyclophosphamid], 3 × Hemihepatectomy
4 30 f Parotis carcinoma CT LO Multiple surgery; Radiation; 6 × [Paclitaxel/Cisplatin]
5 62 f Ovarian Cancer US, CA 125 PC, FIGO IV ? × [Taxol/Carboplatin]
6 38 f Osteosarcoma
(jaw)
CT LO Multiple surgery
7 51 m Oesophagus
carcinoma
CT LI, LN, MPE 2 × [Radiotherapy+Cisplatin/5-FU]; 2 × [Cisplatin/5-FU]; 7 × [Doxotaxel]
8 65 f Pancreas
carcinoma
MRI LI 6 × [Gemcetabine], Immunotherapy (Survivin)
9 33 m Thyroid carcinoma US, CT, Calcitonin LI, BO Sanostatin, Interferon
10 50 m Pancreas
carcinoma
PET LI CapRI-Study branch A (Radiotherapy, Cisplatin/5-FU, IFN-alpha)
11 64 f Thyroid carcinoma CT, TG LU, LN Radio-Jod Therapy, Sanostatin
12 42 f Colon carcinoma PET LI, LU 6 × Radiotherapie (38,6 GBq I-131); Avastin; ? × [Cisplatin/Carboplatin]
13 54 f Endometrial
cancer
CT LI, PC, AS 8 × [Cisplatin/Adriamycin]; 2 × [Adriamycin/Doxorubicin]; 6 × [Navelbine/
Carboplatin]
14 60 f Lung cancer PET LI 6 × [Carboplatin/Cisplatin/Etoposid]
15 62 m Stomach cancer PET LI, PE, AS 1 × [Irinothekan/5-FU/Folinacid]; 5 × [Etoposid/5-FU/Folinacid]
16 54 f Ovarian cancer CA 125 PC, AS, Figo
IIIC
? × [Taxol/Carboplatin]
LU: lung metastases, LI: liver metastases, LN: lymph node metastases, BM: bone metastases; MI: metastasis in Mediastinum; PC: peritoneal cancerosis, AS: ascites,
MPE: malign pleural effusion; LO: local progress; × [...]: cycles of chemotherapy
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Page 3 of 13realization of the diet. A dietary manual containing
background information, a table with nutritional con-
tents of the most important foods, a food exchange list
and recipes for baked goods containing extremely low
amounts of CHO was provided to the patients to assist
with education and compliance. For variety in the daily
menu, a regularly up-dated brochure containing recipes
for cakes and sweets consistent with the diet’s principles
was provided. In general, the amount and type of food
intake was permitted ad libitum, however, with several
essential guidelines:
a) The overall CHO intake was limited to 70 g per day
and 20 g per meal (the patients were instructed to
reduce their CHO even more, if possible). In order to
fulfill this precept, the patients were briefed to follow
the essential rules given in Table 2.
b) The diet plan contained two substantial liquid
meals to be taken as snacks morning and afternoon.
These meals were an oil-protein shake with three com-
ponents: 250 ml highly fermented yoghurt-drink, 8 ml
vegetable oil-mixture and 10 g protein preparation (all
Evomed, Darmstadt, Germany, Table 3). The compo-
nents were provided via a nutritional package given to
the patients every two weeks and stored at 4-8°C. The
oil-protein shake was prepared freshly in a blender by
the patient and provided 264 kcal gross energy with 21
g of fat (including 1.3 g omega-3 fatty acids), 5 g of
CHO and 14 g of protein and was well tolerated by all
patients. In order to combat cachexia [36] and to add a
maximum of Omega-3 fatty acids, patients were encour-
aged to add additional servings (1 tablespoon each) of
the oil mixture or other oils from olives, flaxseed and
hempseed to the three principle meals, e.g. added to
salad or curd cheese.
Evaluation
T h ep a t i e n t sw e r es t a g e db yt h e i ra t t e n d i n go n c o l o g i s t
before and at the end of the study to monitor the course
of the disease. The method of staging depended on the
primary tumor and the known metastatic sites. For
some patients we were able to monitor the course of
the disease via tumor markers as well. Information on
staging parameters and tumor markers can be found in
Enrollment    Diet under  
supervision
  End of the  
study 
     
patient briefing 
handout of
- information  brochures 
- control sticks and  
  documentation sheets  
  for urinary ketosis 
3 months of diet
contact with patient 
(personal or via 
telephone) whenever 
the patient had 
questions or at least 
every two weeks 
final consultation after 
12 weeks of diet or if 
patient dropped out 
early
staging
- quality of life
  (ECOG-  QLQ C30) 
- blood samples drawn 
- first nutrition  
  package sent out 
Every two weeks: 
- blood samples drawn
- Quality of life 
  (ECOG-QLQ C30) 
- new nutrition
  package sent out 
staging
- quality of life
  (ECOG QLQ C30) 
- blood samples drawn
-1    0                                       12
   w eeks    
Figure 1 Study design. The course of the study plan, including the
intervals of data acquisition is shown in this diagram.
Table 2 Dietary guidelines for the patients
Rule Description
1 Avoid all types of bread, cake, processed snacks, sweets, potatoes, pasta, rice, polenta, vegetables rich in starch (corn, beans, peas) and cereals.
2 Be aware of hidden sources of CHO in sugar sweetened drinks, candy, chewing gum with sugar, milk and milk products, lunch meat and
some cheeses as well as in most “low fat” products.
3 Fruits are rich in CHO, therefore always calculate the amount and select those which are low in CHO.
4 Vegetables are often rich in CHO - but mainly in dietary fiber, therefore calculate the usable CHO only.
5 If possible, prefer cold-water fish and meat from grazing cattle as protein sources, because of their preferable fatty acid pattern
6 Vegetables and the few fruits allowed should be grown organic
7 As nibbles, select oil-rich nuts (walnuts, brazil nuts, macadamia nuts) and seeds (sunflower), and only occasionally chocolate with very high
cacao content (min. 85%).
Table 3 Composition of the additive foods supplied
during the study
Highly
fermented
yoghurt-drink
Vegetable oil
mixture
Protein
preparation
Ingredients skimmed milk line seed oil milk-protein
plant oil mixture canola oil
pectin walnut oil
MCT
grape seed oil
argan-oil
pumpkin seed
oil,
Energy per 100 g 245 kJ/59 kcal 3730 kJ/891 kcal 1550 kJ/370
kcal
Protein 1,5 g 0 88-90,3 g
Fat 5,1 g 99,9 g 1 g
Saturated FA 1,3 g 36,5 g n.a.
Unsaturated
FA
3,8 g 63,4 n.a.
Omega-3 FA 0,3 g 19,6 g n.a.
CHO 1,7 g 0 0,2 g
n. a. = not analyzed; FA: fatty acids, CHO: carbohydrates, MCT: medium chain
triglyceride.
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production was measured by the patients themselves
(early morning self assessment of ketonuria; Keto Dia-
stix; Bayer Health Care, Leverkusen, Germany) and
documented in a special table handed out at their first
briefing. A stable ketonuria was when at least 0.5 mmol/
l of ketone bodies were documented on more than half
of the days.
Lipid levels, electrolytes, kidney and liver functions
and hematologic parameters as described in the inclu-
sion criteria were assessed at baseline and every two
weeks, or at time of drop out.
To assess how the disease affects the daily life of the
patient, the performance status was monitored by the
EORTC QLQ-C30 (version 2) questionnaire [34] devel-
oped by the European Organization for Research and
Treatment of Cancer [37]. The EORTC QLQ-C30 is
designed to evaluate the global health status, with func-
tional scales including physical, role, emotional, cogni-
tive and social functioning as well as symptom scales
including fatigue, nausea and vomiting, pain, dyspnoea,
insomnia, appetite loss, constipation, diarrhoea and
financial difficulties. The questionnaire was completed
by the patients at the beginning of the study, after every
two weeks, and at the end of the study. We evaluated
quality of life for all patients who completed the
EORTC QLQ-C30 after at least two months on the diet.
Scoring and Statistics
The EORTC QLQ-C30 questionnaires were scored as
described in the EORTC QLQ-C30 Scoring Manual
[38]. Blood parameters and body weight were analysed
for significance using the two-tailed student’st - t e s ta n d
the Prism 4.0 software (GraphPad; Statcon, Witzenhau-
sen, Germany) before and after the diet. Being aware of
the explorative nature of the data obtained, probability
values below 0.02 (global alpha p = 0.05 corrected fol-
lowing the Bonferroni-Holm process for multiple test
procedures [39]) were considered significant.
Results
Trial profile
A trial profile according to the CONSORT-statement
(http://www.consort-statement.org) criteria is given in
Figure 2, althought this study was not a randomized,
controlled trial.
Recruitment of patients
Announcing the study provoked a barrage of applica-
tions from interested cancer patients. However, the
majority of the patients interested were still under stan-
dard therapy or even in a disease free state and thus,
due to the strict inclusion criteria, participation could be
offered to very few of them. Of those, only 16 felt
capable of following the dietary guidelines and thus,
were enrolled in the study. The mean age of patients
was 50.4 years (30-65 years). Among them were 12
women and 4 men with tumors of different entities as
listed in Table 1. All patients enrolled were tumor
patients with advanced to very advanced disease and
they had already completed several therapies (opera-
tions, chemo- and radiotherapies). No further conven-
tional therapeutic options were available to them at
inclusion time. The patients were informed and agreed
to participate in the study.
Course of the diet
As observed in previous trials with ketogenic diets in
adults [40], some patients found it very difficult to com-
ply with a treatment that demands major changes in
lifestyle. A problem mentioned frequently was the incor-
poration of the diet in the context of family life. The
course of the patients’ diet, including reasons for quit-
ting, is summarized in Table 4. Five (31%) of the
patients concluded the study per protocol. The other
patients dropped out of the study earlier. Two of the
patients withdrew from the study during the first two
weeks because they were unable to adhere to the diet
(patient 1) or because of personal problems (patient 2).
Most of our patients were end stage tumor patients and
two patients died from their malignant disease during
the study (patients 7 and 8). One patient dropped out
b e c a u s eh es u f f e r e df r o me xcessive weight loss and
weakness (patient 10). One patient dropped out of the
study early feeling no longer able to stick to the dietary
guidelines (patient 14), one because of resuming che-
motherapy (patient 7) and four abandoned the diet due
to progress of their advanced cancer situation (patients
4, 6, 13 and 15).
All five patients who completed the study were in a
stable disease, however, one of them failed to document
the EORTC QLQ-C30 questionnaires regularly. Of
those keeping to the diet for the whole 12 weeks, 3
(60%) reached a stable ketonuria as measured by early
morning self assessment. Ketonuria was found to vary
between 0.5 and 8 mM/l, predominantly being 1.5-4.0
mM. Stable ketonuria was evident in three other
patients who, however, dropped out due to progression
after 6-8 weeks. Characteristics of typical ketone mea-
surements are shown for three patients reaching ketosis
(Figure 3A) and three patients failing to reach ketosis
(Figure 3B) during the first 50 days of diet.
Feedback from patients showed some problems with
the realization of the diet. Moreover, the acceptance of
the diet varied greatly. We asked the patients how they
rated the feasibility of the diet after at least two weeks
of dieting: very good, good, moderate, poor or very
poor. One patient stated after three days that it was not
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comment on feasibility, two patients rated it very good,
7 patients rated it good, three moderate and one poor.
Quality of life
The initial quality of life, as measured by the EORTC
QLQ-C30 questionnaire, was low in our patients due
to their advanced tumor stage. The global scores, how-
ever, remained relatively stable throughout the
evaluation time (Figure 4A). In addition, physical and
role functioning worsened only slightly over time
(Figure 4B). In patients with normal bowel function,
the diet caused constipation (Figure 4C), whereas those
patients suffering from diarrhoea as a symptom of
their malignant disease observed a change for the bet-
ter on the diet. Five out of 16 patients suffered from
progressive disease and two patients died during the
s t u d y .T h u s ,i tw a sn o ts u r p r i s i n gt h a tt h es y m p t o m s
Assessed for eligibility (n>100)
Baseline interview either on 
the phone or personally
• Analysed if dietary intervention lasted for at least 8 weeks and if  
EORTC-QLQ C30 was completed for at least 8 weeks (n=7)
• Excluded from analysis (n=9)
n=8 intervention discontinued early
n=1 EORTC-QLQ C30 not completed
• Received dietary intervention for the complete duration of the study (n= 5)
• Discontinued intervention (n=8)
n=1: unable to stick to diet
n=6: progressive disease
n=1: death from progressive disease
Allocated to dietary intervention (n= 16)
i Received dietary intervention for at least 4 weeks (n=13)
i Did not receive dietary intervention (give reasons) (n=3)
n=2: unable to stick to diet
n=1: death from progressive disease after 2 weeks
Allocation
Analysis
FollowǦUp
Enrolled in study (n=16)
Enrollment
Excluded (>80%)
• Not meeting inclusion criteria (65%)
Currently receiving chemotherapy or
no measurable tumor lesions
• Refusal to participate (10%)
Changes in lifestyle considered too radical
• Other reasons (5%)
personal problems
too expensive
not the right time for a change in lifestyle
Figure 2 Trial profile flow diagram. A trial profile corresponding to the CONSORT criteria is shown indicating the course of the pilot study.
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(Figure 4D). However, it was striking that emotional
functioning increased slightly and insomnia improved
(Figure 4B+4D). Therefore, at least some of the
patients felt better on the diet.
Blood parameters and leukocyte count
The laboratory parameters at enrollment and after the
intervention period are given in Table 5. CRP was ana-
lyzed at time of enrollment, and two patients had
mildly elevated CRP (patient 4: 8 mg/dl and patient 8:
4 mg/dl), while for the majority only a slight increase
over normal range could be observed (0.9 mg/dl ± 0.7
SD). For those patients sticking to the diet for at least
6 weeks, data were available for six of the patients
analysed for the EORTC QLQ-C30 questionnaires as
well as for five additional patients, all of which were
analyzed for significant changes. Data are shown in
Figure 5.
Two patients had elevated glucose levels before start-
ing the diet, that returned to normal (patient 10 from
168 to 79 mg/dl; patient 13: 159 to 84 mg/dl). Two had
slightly elevated cholesterol levels before the diet
(patient 11: 221 mg/dl, patient 16: 231 mg/dl), which
dropped during the diet (patient 11: 178 mg/dl, patient
16: 223 mg/dl), one had slightly elevated blood triglycer-
ides which normalized through the course of the diet
(patient 13 from 179 to 159 mg/dl) and one had ele-
vated liver parameters (serum glutamic-pyruvic transa-
m i n a s e ,A L T ;p a t i e n t1 1 )w h i c hf e l ld u r i n gt h e
intervention period from 46 U/l to within normal range,
29 U/l. Of the two patients exhibiting excessively low
leukocyte counts, one (patient 9) showed a slight
increase while one (patient 12) showed a further reduc-
tion in this parameter.
Table 4 Duration of study, reasons for drop out
No Duration of
diet (weeks)
Ketosis > 0.5 mmol/l
(% of days)
Diet
rating
EORTC > 2
months
Laboratory parameters
evaluated for statistics
Result Reason for drop out
1 < 1 - - - ? Drop out after 3 days because of
vomiting, fatigue
2 < 2 - + - ? Drop out after 10 days because
of family problems
3 12 61% +++ yes yes SD
4 8 - + yes yes progress Impaired food intake
5 12 25% ++ yes yes SD
66 97% ++ - yes progress Impaired food intake
7 2 - o - - death
8 5 - - - - death
9 12 78% ++ yes yes SD
10 6 22% + - yes progress Very advanced stage with fatigue
and eating problems
11 12 25% ++ yes yes SD
12 7 44% ++ - yes progress Resumption of chemotherapy
13 8 88% ++ yes yes progress Massive ascites, impaired food
intake
14 4 - o - - ? Felt unable to continue the diet
15 7 60% ++ - yes progress Impaired food intake
16 12 100% +++ yes yes SD
SD: stable disease; diet rating: [+++] very good; [++] good; [+] moderate; [-] poor/not feasible; [o] no comment on feasibility.
Ketosis reached
day
m
m
o
l
/
l
0 10 20 30 40 50
0
2
4
6
8
Patient 16
Patient 9
Patient 15
Ketosis not reached
day
m
m
o
l
/
l
0 10 20 30 40 50
0
2
4
6
8
Patient 10
Patient 12
Patient 11
Figure 3 Course of urinary ketones. Typical examples of urinary
ketone data are shown for three patients reaching ketonuria (A)
and three who failed to reach ketonuria on the majority of days (B).
The first 50 days of the intervention period are shown.
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HDL as well as LDL levels were reduced significantly
after 6 weeks of dieting (see Table 5 and Figure 5).
Since the reduction of LDL (108 ± 36 SD to 92 ± 45 SD
mg/dl; p < 0.01) was more pronounced than that of
HDL (61 ± 19 SD to 52 ± 17 SD mg/dl; p = 0.02), the
LDL/HDL relation as a cardiovascular risk indicator
decreased in the patients (from a mean of 1.9 ± 1.0 SD
to 1.7 ± 0.9 SD; p < 0.01). The serum triglycerides
increased from 89 ± 51 SD in mean to 131 ± 47 SD in
mean, albeit the difference was not significant due to
the broad variance of data. While the level of creatinine
and albumin in sera remained stable, the blood urea
nitrogen increased from 31.7 ± 12.6 SD to 37.8 ± 19.4
SD mg/dl (p < 0.0001), still within normal range. ALT
as parameter for liver function declined to the better
from 29.9 ± 22.2 SD to 25.9 ± 11.9 SD (p < 0.01). The
total leukocyte count significantly increased from 5.5 ±
1.5 SD to 6.4 ± 1.2 SD × 1000/µl; p < 0.001 during the
observation time.
One patient (13) suffered from diabetes as concomi-
tant disease and reported a decreased (75% of initial
units) insulin requirement during the study. With the
exception of one patient (15), all patients showed
reduced blood glucose levels on the diet.
Body weight, BMI, albumin
The body weight of 7 patients was obtained at starting
point and after 6-8 weeks of dieting. As described for
diets low in CHO, all patients significantly lost weight
during the diet. However, with the exception of one
patient (no. 13) who intended to use the diet to reduce
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Figure 4 Quality of life. Summary of the EORTC QLQ-C30 (version 2) questionnaires. A): Global health status and functional score remained
relatively stable during the time evaluated while the global symptom score increased slightly. B) Subdivision of functional scores shows a slight
decrease in physical and role functioning, an increase in emotional functioning and stable cognitive as well as social functioning. C) Concerning
digestive functions, the symptoms score showed an increase in appetite loss, constipation or diarrhoea in the first four weeks of the diet.
Symptoms then remain stable and signs of diarrhoea diminish. D) The other symptoms were an increase in fatigue and pain corresponding to
the very advanced tumor situation. However, insomnia clearly decreased with ongoing dieting. Graphs are given as means for the seven
evaluable patients.
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Page 8 of 13her obesity and lost 10 kg (in part, the extreme weight
fluctuation observed in this patient was generated by
recurrent ascites which was punctured three times dur-
ing the study), the patients lost an average of 2 kg (from
68.5 ± 6.8 SD to 66.5 ± 6.8 SD; p < 0.05); consequently
BMI was reduced from mean 23.5 ± 6.0 SD to 22.5 ±
5.4 SD.
Influence on the tumor itself
A statistical evaluation of the effect of the diet on tumor
characteristics is not feasible, due to the low number
and heterogeneity of patients enrolled in our study.
I n s t e a d ,ad e s c r i p t i o no ft h ec o u r s eo fd i s e a s ei sg i v e n :
Four patients who dropped out of the study early were
not evaluated, two patients died early. Progress of dis-
ease occurred in 5 patients who then discontinued the
diet, whereas 5 of the patients who adhered to the diet
throughout the study had stable disease (Table 4).
Discussion
In this pilot study, we evaluated the safety (occurrence
of side effects), feasibility (following the dietary guide-
lines for advanced cancer patients) and impact (on body
weight, laboratory parameters, quality of life) of a Low-
Carb/HighFat (LCHF) diet very low in carbohydrates
(CHO) and rich in fat and protein on a heterogeneous
group of advanced cancer patients. Announcing the
study provoked a broad interest of media and the hospi-
tal was overwhelmed with enquiries from cancer
patients. This reflects the enormous interest of cancer
patients in complementary and alternative methods of
improving their situation via change of lifestyle and,
especially, their diet [41,42]. However, most of the
patients interested were either end-stage (hoping for a
“miraculous cancer cure”) or disease free after primary
therapy, intending to use the diet for prevention of
relapse. Both groups were not eligible, thus reducing the
number of patients fulfilling the requirements to very
few. It should be noted in this respect, that due to the
heterogeneity of the patients included and the nature of
this diet with normal food, this study was a series of
cases and neither randomized nor blinded.
As described in previous studies [40], we found an
LCHF treatment in adult patients to be only slightly fea-
sible. Based on our observations, an LCHF diet is not an
option for all patients with advanced cancer, since the
associated changes in eating habits (e.g. waiving soft
drinks and beer) are not acceptable for some of them.
For other patients however, an LCHF diet might be an
option for increasing their quality of life. The latter
belong to the group of patients who want to actively
i n f l u e n c et h ec o u r s eo ft h ed i s e a s e( b yc h a n g eo fl i f e -
style) and who are in a phase of their disease where
cooking and eating are not hampered. Although there
Table 5 Blood parameters
Param.: CRP Glucose HBA1c Chol. LDL HDL Triglyc. Crea. Urea ALT Alb Leuc.
Units mg/dl mg/dl % mg/dl mg/dl mg/dl mg/dl mg/dl mg/dl U/l d/dl N*1000/µl
Norm-range 0-0, 5 <120 130-220 0-150 > = 35 74-172 0 - 0,95 10 - 50 < = 35 3,5-5,5 5 - 10
N o w k S SES ESESE S E SES ES E S ES ES E
1 < 1 0,77 109 - - - - - - - - - - - 0,6 - 28,6 - 50,4 - 4,3 - 7,0 -
2 < 2 0,6 86 - - - 231 - 130 - 88 - 63 - 0,7 - 32,1 - 16,2 - 4,2 - 3,6 -
3 12 0,6 91 90 5,8 5,3 104 119 32 38 65 65 34 78 0,8 0,7 36,4 42,6 23,1 25,3 4,4 4,1 4,5 4,2
4 8 8,1 117 103 - 5,7 - 201 - 129 47 49 88 80 0,4 0,5 23,0 19,0 24,0 29,0 - - 5,4 6,3
5 12 0,4 91 87 5,6 5,4 197 204 115 104 46 52 178 - 0,7 0,6 27,3 23,0 29,0 19,0 4,4 4,8 7,5 6,2
6 6 - 72 - 5,4 - 139 - 58 - 74 - 34 - 0,6 0,6 20,3 29,1 15,5 17,8 5,0 4,8 5,5 7,6
7 2 1,91 84 - 5,7 - - - - - - - - 0,7 - 12,1 - 10,3 - 3,4 - 4,2 -
8 5 4,0 101 89 - - - - - - - - - - 0,7 0,7 26,9 49 12,4 16,0 4,0 3,6 7,3 11
9 12 1,9 87 78 4,7 4,9 - 79 - 16 - 26 - 185 0,7 0,8 27,0 31,2 58,0 56,6 4,8 4,0 2,9 3,1
10 6 - 168 79 5,3 - 190 193 124 117 52 40 71 179 0,8 1 40,9 35,4 90,2 - 4,2 - 7,4 8,5
11 12 0,18 112 94 5,4 - 221 178 117 81 85 80 97 84 0,8 0,6 30 26 15,7 15,7 4,3 4,4 5,2 5,8
12 7 - 94 95 4,7 - - - 146 152 - - - - 0,6 0,6 - - 46 29 - 3,0 4,1 3,1
13 8 0,89 159 84 5,5 - 193 165 117 - 40 - 179 159 1,6 0,9 35,4 35,0 11,2 19,3 3,2 3,2 7,4 8,5
14 4 - 106 - - - - - - - - - - - - - - - - - - - - -
15 7 0,1 85 134 5,2 - 155 127 107 65 35 39 65 114 1,4 1,4 67,4 90,3 23,8 35,2 4,1 3,6 5,3 6,0
16 12 2 79 85 5,5 - 231 223 138 125 77 65 82 167 0,7 0,6 35,7 35,0 22,8 22,4 4,8 4,1 5,1 6,5
n 12 16 11 11 4 9 9 10 9 10 8 10 8 15 12 14 11 15 11 13 10 15 12
ME 1,8 103 93 5,3 5,3 185 165 108 92 61 52 89 131 0,8 0,8 31,7 37,8 29,9 25,9 4,2 4,0 5,5 6,4
SD 2,3 27 16 0,4 0,3 44 48 36 45 19 17 51 47 0,3 0,3 12,6 19,4 22,2 11,9 0,5 0,6 1,5 1,2
No: patient number; wk: weeks of diet; S: start of study; E: end of study, first blood at > = 4 weeks; ME: mean; SD: standard deviation.
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Page 9 of 13was a worsening in some parameters of the quality of
life assessment, reflecting the very advanced situation of
our patients, we found an improvement in emotional
functioning and insomnia, even though the course of
the disease in our patients was progressive or in the
best case, stable. Certainly, we cannot exclude the possi-
bility of a placebo effect caused by a) the intensive con-
sultation and briefing of the patients and b) the chance
for patients to actively participate in their therapy.
Further, anecdotic evidence links the presence of ketone
bodies to a mild euphoria [43] which was assumed to be
caused by one of the ketone bodies, beta-hydroxybuty-
rate. Thus, this metabolic state of ketosis, which was
reached by six of our patients, could be the reason for
the improvement in our patients, too.
Diets high in fat (up to 90%) and very low in CHO,
inducing a stable ketosis, have been used for a long time
to treat epilepsy and adiposity. The most frequent side
effects reported so far are constipation, vomiting, lack of
energy and hunger [20]. These symptoms were reported
by our patients slightly more often within the first 4
weeks of the diet. However, none of them complained
of hunger, and nausea and vomiting were very rare. We
could also not determine from our data, whether the
observed increase in fatigue was caused by the diet or
by the progress of disease. In this context we can also
report, that patients outside the study and following the
diet during standard therapies (chemo-, radiotherapy),
regularly report an increase in energy and condition
(not shown).
The time frame of the study was selected according to
common duration of studies dealing with the application
of ketogenic diets in epilepsy patients [20,40] and based
on the short survival perspective of the patients
enrolled. Further, the Nebeling study showed that the
effects of a ketogenic diet were not visible until after 8
weeks [26]. Since our patient group was small and
diverse, we cannot comment on the influence of the
LCHF diet on the course of disease. The influence of
the diet on specific tumor entities or on tumors with
different molecular characteristics concerning glucose
metabolism must be evaluated in further studies.
The present study has several limitations. Only few
patients fulfilled the requirements and all of them were
in a very advanced stage of disease, as reflected by the
two early death cases and the progress of disease in five
cases which made it impossible for those patients to fol-
l o wt h ed i e tf o rt h ew h o l et i m e .S i n c ew ea i m e dt ot e s t
the acceptability and compatibility of an LCHF diet in
advanced cancer patients, we did not select patients
according to their tumors. Therefore, the group was
very inhomogeneous. Further, the majority of the study
participants were not from our own hospital, but scat-
tered all over Germany and blood samples and labora-
tory parameters had to be provided by their family
doctors or local oncologists.
Compared to KD regimens for the treatment of epi-
lepsy or obesity that reduce the amount of CHO allowed
to at least 10-25 g per day, our LCHF protocol allowed
up to 70 g CHO/day. This larger amount was allowed
due to several considerations: 1) The daily glucose pro-
duction rate in healthy patients was determined to be
around 3.6 µmol/kg/min (corresponding to 0.933 g/kg/
day) with a very stable rate of gluconeogenesis of 2.6
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Figure 5 Blood parameters. The courses of the blood parameters
for the 11 evaluable patients at start of study and after at least 6
weeks of dieting are shown. While the blood glucose (A), creatinine
(B), albumin (C) and triglycerides (D) did not change much,
leukocyte count increased significantly (E) and cholesterol (F), LDL
(G) and LDL/HDL (H) decreased significantly. The patients’, ALT
dropped significantly (I) while blood urea increased, albeit
remaining in normal range (J). Dotted lines: upper and lower level
of normal range.
Schmidt et al. Nutrition & Metabolism 2011, 8:54
http://www.nutritionandmetabolism.com/content/8/1/54
Page 10 of 13µmol/kg/min (corresponding to 0.67 g/kg/day) and a
variable rate of glycogenolysis. The latter depends on
the amount of glucose/protein and, if too much CHO
w a st a k e nu p ,g l u c o s ew a ss t o r e da sg l y c o g e n[ 4 4 ] .2 )
Increased rates of gluconeogenesis, which burns the
body’s lean mass and harms the patient, have been
documented in patients with malignant disease [45].
Thus, advanced cancer patients hypothetically may tol-
erate a little more CHO in their diet without leaving the
metabolic state ketosis. 3) The larger amounts of CHO
allow patients to add yoghurt and some vegetables/
fruits, which although containing milk or fruit sugar, are
also promoted to be beneficial to cancer patients [46]
and - based on the popularity of these books - very wel-
comed by our patients. These facts in mind, allowing a
little more CHO in the diet should not severely influ-
ence the ketogenic effect and indeed, 6 of the 11
patients on the diet for at least 6 weeks reached ketosis.
More CHO facilitates the selection and compilation of
food and thus increases the compliance of the patients.
From data available, we cannot determine the reasons
for the failure of the remaining patients to reach a stable
ketosis. It could be speculated in this respect, that either
the amount of CHO allowed was over the individual
ketogenetic limit, or the patients consumed additional
CHO without documenting it. The method for analyzing
urinary ketones does not seem to be the cause of nega-
tive results, since this method shows values that corre-
late highly with blood ketone values in a preliminary
test series (not shown) and was already described in lit-
erature to show a good correlation to blood ketones in
long time ketosis [47]. However, to help achieve a stable
ketosis state in further trials, a step-by step induction of
ketosis as suggested by Atkins [22] may be necessary,
with a CHO content of the diet customized to the pre-
servation of ketosis in each individual patient.
The significant reduction of body weight (and BMI)
observed in all patients could reflect the typical effect
observed in the early phase of low-carbohydrate diets -
usually not restricted in calories. Here, the maximum
weight loss was normally observed within the first 6
months of the diet [25,48,49]. In contrast to the weight
loss observed in our group and described in general for
ketogenic diets, a non-ketogenic high-fat diet (mixture
of normal meals with an additional fat-enriched artificial
liquid diet) supported the maintenance of body weight
in patients with gastrointestinal tumors [36]. However,
those patients were not “end stage” and the diet was fol-
lowed during chemotherapy. Yet, based on their find-
ings, it could be speculated that the application of an
LCHF diet in an earlier phase of tumor disease might be
of greater benefit for the patient.
Among the study patients and treating oncologists,
many concerns were expressed that a diet very rich in
total fat could adversely affect blood lipid levels or
immune status. In accordance to data published in sev-
eral extended studies applying low-carb diets to obese
patients to lose weight [25,48,49], the cholesterol and
especially LDL/HDL values of our patients significantly
improved. The exception to this pattern is the triglycer-
ide concentration. Other than described in the cases of
ketogenic diets for the reduction of body weight [49],
the levels of triglycerides in our patient’s sera increased
on the diet, albeit not to a significant level, and still in
normal range. This effect was also observed by Mosek
[40] and thus may reflect a normalization of the trigly-
ceride level in non-overweight patients. However, we
have not investigated subpopulations of immune cells,
other than described in Breitkreutz [36] who observed a
significant decrease in total leucocyte count in the
group of patients on the fat rich diet. The leucocyte
count in our patients significantly increased to the bet-
ter. This difference may be due to different settings and
the accompanying chemotherapy of the patients in the
former study.
Since several studies have shown that supplementation
with Omega-3 fatty acids (FA) benefits patients with
advanced cancer and weight loss [50-52], the vegetable
oil used in the oil-protein shake taken by the patients
two times a day was especially enriched in Omega-3 FA.
Further, the patients were encouraged to snack on nuts
and seeds rich in Omega-3 FA such as flaxseed, hemp-
seed and walnuts. However, the study was too short and
the patients presumably too advanced in their disease to
observe a beneficial effect on tumor growth as described
in animal models [31,32,53].
When we started the study in 2007, except for two
preliminary reports [26,54], no protocol was available on
how to perform an LCHF or ketogenic diet study with
cancer patients. Since then, a study protocol was pub-
lished by Fine et al. [55], and four clinical trials were
registered in the clinical trials database [56]. However,
no patient’s data resulting from these studies have been
published so far. Thus, it will be very interesting to see
if the slightly different nutritional settings of LCHF or
ketogenic diets will benefit the study patients as well.
Conclusions
A carbohydrate-restricted fat rich diet was well tolerated
b y5o f1 6p a t i e n t sf o r3m o n t h sa n da n o t h e r7f o ra t
least 5 weeks until progression or death. No adverse
laboratory effects were observed, but there was ongoing
weight loss. The data of this pilot study further suggest
that a KD might improve quality of life and classical
blood parameters in some patients with advanced meta-
s t a t i ct u m o r s .H o w e v e r ,t oj u d g ee f f e c t so nq u a l i t yo f
life or cancer progression, randomized studies with suf-
ficient numbers of patients are needed.
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